Browse SLC12A2

Summary
SymbolSLC12A2
Namesolute carrier family 12 (sodium/potassium/chloride transporter), member 2
Aliases NKCC1; BSC; BSC2; PPP1R141; bumetanide-sensitive sodium-(potassium)-chloride cotransporter 1; basolateral Na ......
Chromosomal Location5q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane; Multi-pass membrane protein.
Domain PF00324 Amino acid permease
PF08403 Amino acid permease N-terminal
PF03522 Solute carrier family 12
Function

Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.

> Gene Ontology
 
Biological Process GO:0006813 potassium ion transport
GO:0006814 sodium ion transport
GO:0006820 anion transport
GO:0006821 chloride transport
GO:0006884 cell volume homeostasis
GO:0006970 response to osmotic stress
GO:0006972 hyperosmotic response
GO:0007214 gamma-aminobutyric acid signaling pathway
GO:0007568 aging
GO:0008361 regulation of cell size
GO:0015672 monovalent inorganic cation transport
GO:0015696 ammonium transport
GO:0015698 inorganic anion transport
GO:0030321 transepithelial chloride transport
GO:0032535 regulation of cellular component size
GO:0045795 positive regulation of cell volume
GO:0070633 transepithelial transport
GO:0070634 transepithelial ammonium transport
GO:0072488 ammonium transmembrane transport
GO:0090066 regulation of anatomical structure size
GO:0098656 anion transmembrane transport
GO:0098661 inorganic anion transmembrane transport
GO:1902476 chloride transmembrane transport
Molecular Function GO:0008509 anion transmembrane transporter activity
GO:0008511 sodium:potassium:chloride symporter activity
GO:0008519 ammonium transmembrane transporter activity
GO:0015103 inorganic anion transmembrane transporter activity
GO:0015108 chloride transmembrane transporter activity
GO:0015291 secondary active transmembrane transporter activity
GO:0015293 symporter activity
GO:0015294 solute:cation symporter activity
GO:0015296 anion:cation symporter activity
GO:0015377 cation:chloride symporter activity
GO:0022804 active transmembrane transporter activity
GO:0022853 active ion transmembrane transporter activity
Cellular Component GO:0016324 apical plasma membrane
GO:0045177 apical part of cell
> KEGG and Reactome Pathway
 
KEGG hsa04970 Salivary secretion
hsa04972 Pancreatic secretion
Reactome R-HSA-426117: Cation-coupled Chloride cotransporters
R-HSA-425407: SLC-mediated transmembrane transport
R-HSA-382551: Transmembrane transport of small molecules
R-HSA-425393: Transport of inorganic cations/anions and amino acids/oligopeptides
Summary
SymbolSLC12A2
Namesolute carrier family 12 (sodium/potassium/chloride transporter), member 2
Aliases NKCC1; BSC; BSC2; PPP1R141; bumetanide-sensitive sodium-(potassium)-chloride cotransporter 1; basolateral Na ......
Chromosomal Location5q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SLC12A2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolSLC12A2
Namesolute carrier family 12 (sodium/potassium/chloride transporter), member 2
Aliases NKCC1; BSC; BSC2; PPP1R141; bumetanide-sensitive sodium-(potassium)-chloride cotransporter 1; basolateral Na ......
Chromosomal Location5q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SLC12A2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -1.96; FDR: 0.04630 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolSLC12A2
Namesolute carrier family 12 (sodium/potassium/chloride transporter), member 2
Aliases NKCC1; BSC; BSC2; PPP1R141; bumetanide-sensitive sodium-(potassium)-chloride cotransporter 1; basolateral Na ......
Chromosomal Location5q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SLC12A2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2760.42
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2230.866
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3210.726
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1080.746
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3640.857
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.7060.786
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2540.521
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.110.94
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.6120.714
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0070.994
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.6070.13
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1830.107
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SLC12A2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.1011.10.0181
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.1011.10.0286
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 1113015.4-15.40.482
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 512016.7-16.71
Summary
SymbolSLC12A2
Namesolute carrier family 12 (sodium/potassium/chloride transporter), member 2
Aliases NKCC1; BSC; BSC2; PPP1R141; bumetanide-sensitive sodium-(potassium)-chloride cotransporter 1; basolateral Na ......
Chromosomal Location5q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SLC12A2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSLC12A2
Namesolute carrier family 12 (sodium/potassium/chloride transporter), member 2
Aliases NKCC1; BSC; BSC2; PPP1R141; bumetanide-sensitive sodium-(potassium)-chloride cotransporter 1; basolateral Na ......
Chromosomal Location5q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SLC12A2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SLC12A2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSLC12A2
Namesolute carrier family 12 (sodium/potassium/chloride transporter), member 2
Aliases NKCC1; BSC; BSC2; PPP1R141; bumetanide-sensitive sodium-(potassium)-chloride cotransporter 1; basolateral Na ......
Chromosomal Location5q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SLC12A2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSLC12A2
Namesolute carrier family 12 (sodium/potassium/chloride transporter), member 2
Aliases NKCC1; BSC; BSC2; PPP1R141; bumetanide-sensitive sodium-(potassium)-chloride cotransporter 1; basolateral Na ......
Chromosomal Location5q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SLC12A2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSLC12A2
Namesolute carrier family 12 (sodium/potassium/chloride transporter), member 2
Aliases NKCC1; BSC; BSC2; PPP1R141; bumetanide-sensitive sodium-(potassium)-chloride cotransporter 1; basolateral Na ......
Chromosomal Location5q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SLC12A2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSLC12A2
Namesolute carrier family 12 (sodium/potassium/chloride transporter), member 2
Aliases NKCC1; BSC; BSC2; PPP1R141; bumetanide-sensitive sodium-(potassium)-chloride cotransporter 1; basolateral Na ......
Chromosomal Location5q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SLC12A2 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting SLC12A2.
ID Name Drug Type Targets #Targets
DB00761Potassium ChlorideSmall MoleculeSLC12A1, SLC12A2, SLC12A4, SLC12A5, SLC12A6, SLC12A76
DB00887BumetanideSmall MoleculeCFTR, SLC12A1, SLC12A2, SLC12A4, SLC12A55
DB01325QuinethazoneSmall MoleculeCA1, CA2, SLC12A1, SLC12A2, SLC12A35